Literature DB >> 15026358

A mimic of tumor rejection antigen-associated carbohydrates mediates an antitumor cellular response.

Behjatolah Monzavi-Karbassi1, Ping Luo, Fariba Jousheghany, Marta Torres-Quiñones, Gina Cunto-Amesty, Cecile Artaud, Thomas Kieber-Emmons.   

Abstract

Tumor-associated carbohydrate antigens are typically perceived as inadequate targets for generating tumor-specific cellular responses. Lectin profile reactivity and crystallographic studies demonstrate that MHC class I molecules can present to the immune system posttranslationally modified cytosolic peptides carrying O-beta-linked N-acetylglucosamine (GlcNAc). Here we report that a peptide surrogate of GlcNAc can facilitate an in vivo tumor-specific cellular response to established Meth A tumors that display native O-GlcNAc glycoproteins on the tumor cell surface. Peptide immunization of tumor-bearing mice had a moderate effect on tumor regression. Inclusion of interleukin 12 in the immunization regimen stimulated complete elimination of tumor cells in all of the mice tested, whereas interleukin 12 administration alone afforded no tumor growth inhibition. Adoptive transfer of immune T cells into tumor-bearing nude mice indicates a role for CD8+ T cells in tumor regression. This work postulates that peptide mimetics of glycosylated tumor rejection antigens might be further developed for immune therapy of cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15026358     DOI: 10.1158/0008-5472.can-03-1532

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

Review 1.  Antibodies: At The Nexus of Antigens and Cancer Vaccines.

Authors:  Zenon Steplewski; Magdalena Thurin; Thomas Kieber-Emmons
Journal:  J Infect Dis       Date:  2015-07-15       Impact factor: 5.226

2.  Moving a Carbohydrate Mimetic Peptide into the clinic.

Authors:  Issam Makhoul; Laura Hutchins; Peter D Emanuel; Angela Pennisi; Eric Siegel; Fariba Jousheghany; Behjatolah Monzavi-Karbassi; Thomas Kieber-Emmons
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

3.  Peptides mimicking GD2 ganglioside elicit cellular, humoral and tumor-protective immune responses in mice.

Authors:  Assefa Wondimu; Tianqian Zhang; Thomas Kieber-Emmons; Phyllis Gimotty; Katrin Sproesser; Rajasekharan Somasundaram; Soldano Ferrone; Chun-Yen Tsao; Dorothee Herlyn
Journal:  Cancer Immunol Immunother       Date:  2008-07       Impact factor: 6.968

Review 4.  Bridging innate and adaptive antitumor immunity targeting glycans.

Authors:  Anastas Pashov; Bejatolah Monzavi-Karbassi; Gajendra P S Raghava; Thomas Kieber-Emmons
Journal:  J Biomed Biotechnol       Date:  2010-06-15

Review 5.  Cancer vaccine with mimotopes of tumor-associated carbohydrate antigens.

Authors:  Danuta Kozbor
Journal:  Immunol Res       Date:  2010-03       Impact factor: 2.829

6.  Immunization with a mimotope of GD2 ganglioside induces CD8+ T cells that recognize cell adhesion molecules on tumor cells.

Authors:  Andrzej Wierzbicki; Margaret Gil; Michael Ciesielski; Robert A Fenstermaker; Yutaro Kaneko; Hanna Rokita; Joseph T Lau; Danuta Kozbor
Journal:  J Immunol       Date:  2008-11-01       Impact factor: 5.422

7.  The promise of the anti-idiotype concept.

Authors:  Thomas Kieber-Emmons; Bejatohlah Monzavi-Karbassi; Anastas Pashov; Somdutta Saha; Ramachandran Murali; Heinz Kohler
Journal:  Front Oncol       Date:  2012-12-19       Impact factor: 6.244

Review 8.  Tumor-Associated Glycans and Immune Surveillance.

Authors:  Behjatolah Monzavi-Karbassi; Anastas Pashov; Thomas Kieber-Emmons
Journal:  Vaccines (Basel)       Date:  2013-06-17

9.  Carbohydrate mimetic peptides augment carbohydrate-reactive immune responses in the absence of immune pathology.

Authors:  Leah Hennings; Cecile Artaud; Fariba Jousheghany; Behjatolah Monzavi-Karbassi; Anastas Pashov; Thomas Kieber-Emmons
Journal:  Cancers (Basel)       Date:  2011-11-11       Impact factor: 6.639

Review 10.  Carbohydrate-mimetic peptides for pan anti-tumor responses.

Authors:  Thomas Kieber-Emmons; Somdutta Saha; Anastas Pashov; Behjatolah Monzavi-Karbassi; Ramachandran Murali
Journal:  Front Immunol       Date:  2014-06-30       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.